A Hong Kong biotech start-up is working with a number of university partners to conduct global clinical trials that could lead to a better way of delivering drugs for prevalent eye diseases.

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off. The Massachusetts-based biotech said a ...

The risk of systemic side effects is greater in infants than in adults due to increased percutaneous drug absorption and lower blood volume. The closed eyes technique of eyedrop administration is ...

It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic retinopathy. Keep reading to learn about the common, mild, and serious side effects that ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...

A couple who moved from Colorado to Prescott says U-Haul lost one of their moving pods so they called On Your Side. A Mesa woman got scammed out of $1,500 when the engine she bought never showed ...

The biotech industry’s DeepSeek moment came last fall.

If you ever notice pesky dark strands that may resemble anything from a simple speck to a cobweb drifting across your vision, what you're probably seeing is what's known as an eye floater. Floaters ...

Nanocarriers are promising in tumour-targeting drug delivery but limited by their delivery efficiency within tumour microenvironment (TME). Here the authors report the development of lipoic acid ...